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ABSTRACT 
Regulating the time of ovulation in the mare has many practical and beneficial 
management applications, including use with artificial insemination.   The objective 
of the present study was to test the effectiveness of Cystorelin™ (gonadorelin 
diacetate tetrahydrate) to elicit increased LH secretion and to induce ovulation in 
cyclic mares.  A total of 24 mares of Thoroughbred and stock type breeding was 
used in this study.  Mares possessing an ovarian follicle 3.5 cm to 4.0 cm in 
diameter were assigned to either treatment with three 75 µg (1.5 mL) i.m. injections 
of Cystorelin™ or three 1.5 mL i.m. injections of sterile saline (control).   Treatment 
with Cystorelin™ reduced (P < .05) the mean number of days until ovulation (2.25 ± 
0.25 vs 3.23 ± 0.41 for Cystorelin™ and saline, respectively), although variation in 
the time to ovulation was similar (P>.81).  Mean plasma LH levels were calculated 
over four time periods (-30 to 0 (Period 1), 30-120 (Period 2), 150-240 (Period 3), 
270-360 min (Period 4)).  Luteinizing hormone response was analyzed by comparing 
the mean LH value of Period 1, 2, and 3 with the baseline mean.  Although the level 
in Period 2 tended (P<.07) to be higher than baseline, LH levels in Periods 3 and 4 
were not different from baseline (P>.15, P>.18 respectively).  In summary 
Cystorelin™ effectively hastened ovulation in mares. Further research is necessary 
to develop a protocol that can also reduce variability in the time of ovulation.    
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CHAPTER 1. LITERATURE REVIEW 
1.1 Introduction 
 Regulating the time of ovulation in the mare has many practical and beneficial 
applications and the increasing use of artificial insemination technologies in the 
equine industry has increased the importance of controlling the time of ovulation in 
the mare.  Controlling the time of ovulation can increase management and labor 
efficiency, optimize the time of breeding when using transported semen, and reduce 
the number of times a mare is bred during a given estrous cycle.  In cyclic mares, 
human chorionic gonadotropin (hCG), prostaglandin F2alpha (PGF2α) (and 
analogues), and gonadotropin releasing hormone (GnRH) have been used in 
attempts to control the time of ovulation.  A new product to time ovulation in the 
mare, EquiPure-LH (by AspenBio Pharma) has been sold as a specially labeled 
reagent to licensed veterinarians since late 2005.  AspenBio Pharma is seeking U.S. 
Food and Drug Administration (FDA) approval.  Apparently, no research has been 
published on the efficacy of EquiPure-LH in hastening ovulation in mares.   
The repeated use of hCG can result in reduced effectiveness to time 
ovulation due to its antigenic effects in the mare (Sullivan et al., 1973; Voss et al., 
1975; Roser et al., 1979; Duchamp et al., 1987; McCue et al., 2004). The use of 
PGF2α (and analogues) to time ovulation has resulted in inconsistent responses 
(Harrison et al,. 1987; Savage and Liptrap, 1987; Squires et al., 1981).  The GnRH 
analogue, deslorelin (Ovuplant™), has been reported to cause desensitization to 
GnRH and suppressed gonadotropin secretion which leads to an extended interval 
between induced ovulation and the subsequent ovulation if the mare is not pregnant 
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when Ovuplant™ is left in place for over 48 hours (McCue et al,. 2000; Johnson and 
CartMill, 2002).   
1.2 Seasonality 
 The mare is a seasonally polyestrous breeder.  Photoperiod is the most 
important external factor influencing seasonality in the mare, as is the case for many 
other species (Ginther, 1992).  The pineal gland receives an environmental cue to 
decrease melatonin secretion during daylight hours; hence, melatonin is secreted 
during hours of darkness.  While the hypothalamic-pituitary-gonadal axis is under the 
influence of melatonin, GnRH secretion is decreased, resulting in a non-reproductive 
state (Nagy, 2000).   Short daylength is associated with reproductively inactive 
mares.  As daylength increases, melatonin secretion is decreased allowing an 
increase in the secretion of GnRH and subsequent reproductive cyclicity of the mare 
(Figure 1).  
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Figure 1. Pineal gland control of reproductive seasonality in mares. 
 
Reproduced with permission from Geisert, R., 2005 
 
Many terms are used to categorize the time of year the mare is able to 
reproduce such as the breeding, active, estrous, and ovulatory seasons.  Anestrous, 
dormant, anovulatory, acyclic, and nonbreeding season are terms used to describe 
the time of the year when mares are not able to reproduce (Ginther, 1992).  For this 
thesis the terms estrous season and anestrous season will be used.  The majority of 
mares in the northern hemisphere are in their estrous season during the spring and 
summer and in their anestrous season during the fall and winter.  The early fall and 
early spring serve as transition periods from estrous to anestrous seasons and from 
anestrous to estrous seasons, respectively.    
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1.2.1 Estrous cycle 
The estrous cycle is defined as the repetitive sequence of events that 
prepares the mare for conception (McKinnon and Voss, 1993).  The estrous cycle 
can be divided into two phases, the follicular phase and the luteal phase.  The 
follicular phase consists of proestrus and estrus stages of the estrous cycle, and the 
luteal phase is comprised of metestrus and diestrus stages.  Estrus is the period in 
which the mare is sexually receptive to the stallion and during which ovulation 
occurs.  Diestrus is the period during which the mare is not sexually receptive to the 
stallion and it is characterized by the presence of a corpus luteum.   The means for 
the lengths of estrus, diestrus, and estrous cycle are 6.5, 14.9, and 21.7 days, 
respectively (Ginther, 1992). 
1.2.2 Follicular waves 
Follicular activity is increased during the estrous season versus the anestrous 
season. Follicular growth is described in two types of follicular waves, major and 
minor waves.  A major follicular wave refers to several follicles that initially grow in 
synchrony but eventually dissociate (Ginther, 1992).  The dissociation of the 
synchronized follicles in the major wave is due to the selection of a dominant follicle.  
The dominant follicle grows to a diameter greater than 30 mm and then either 
regresses (in an anovulatory wave) or ovulates (in an ovulatory wave).  The 
remaining follicles from the major wave regress after the dominant follicle emerges 
(Ginther, 1992; Samper, 2000).   
Major waves can be further categorized into primary or secondary waves.  
Primary major waves emerge at mid-diestrus, resulting in ovulation of the dominant 
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follicle at or near the end of estrus.  If present, secondary major waves precede 
primary major waves and emerge during late estrus or early diestrus.  In secondary 
major waves the dominant follicle ovulates, becomes hemorrhagic, or regresses 
(Ginther, 1992; Samper, 2000).                           
Minor follicular waves also have been identified.  The differences between a 
minor wave and a major wave are the diameter and ovulation of the dominant 
follicle.  With a minor wave the dominant follicle reaches a diameter of less than 30 
mm and then regresses, never reaching ovulation (Samper, 2000).  It appears that 
the minor wave lacks full dominance typically exhibited by a large dominant follicle 
capable of ovulating. 
1.2.3 Hypothalamic-pituitary-gonadal axis 
Fertility depends on a functional hypothalamic-pituitary-gonadal axis, and 
GnRH from the hypothalamus is the primary regulator of reproduction in vertebrates.  
Gonadotropin releasing hormone is released in a pulsatile fashion and travels to the 
pituitary gland via the portal hypophyseal vasculature.  The synthesis and secretion 
of the two gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone 
(FSH), is ultimately regulated by GnRH.  These gonadotropins stimulate sex 
hormone synthesis and gametogenesis in the gonads to ensure reproductive 
competence (Hapgood et al., 2005). 
1.3 GnRH   
Gonadotropin releasing hormone is a decapeptide with a short endogenous 
half life of five to ten minutes (Conn, 1987).  The mammalian GnRH structure (pGlu-
His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly.NH2) was first discovered in 1971 (Schally et 
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al., 1971).  Gonadotropin releasing hormone and its analogues are valuable in 
controlling estrous cycles and the timing of ovulation in many mammalian species.  
Substitutions with D-amino acids in position six stabilizes conformation of GnRH, 
increases binding affinity, and decreases metabolic clearance, thus extending the 
half-life of a GnRH analogue.  This substitution is used in all agonist and antagonist 
analogues.  Hydrophobic D-amino acid substitutions in the first, second and third 
positions at the amino terminus result in antagonist analogues that retain substantial 
receptor binding affinity and reduced agonist activity (Millar, 2004).  
1.3.1 GnRH pulsatile release  
The pattern of GnRH secretion dictates the reproductive status of the mare.  
GnRH pulse frequency and amplitude vary with season and stage of the estrous 
cycle.  Gonadotropin secretion is influenced by and reflects changes in GnRH 
pulsatility.  Hormonal analyses of jugular blood show high amplitude, synchronous 
FSH and LH pulses occur 0-4 times daily during anestrous (Alexander and Irvine, 
1991) and 1-4 times daily during diestrus (Irvine and Alexander, 1993).  The 
frequency of these pulses, long half-life, and large amount of available FSH and LH 
results in low detection of pulses in jugular blood; therefore, it has been found that 
daily blood samples or long window bleedings are adequate to measure FSH and 
LH secretion during the period of estrus (Irvine, 1979; Fitzgerald et al., 1985).   
It was not until a new technology was developed that LH and FSH pulses 
were more adequately measured during estrus.  Intercavernous sinus (ICS) 
cannulation was devised by Irvine and Alexander (1984), allowing for a more 
accurate measurement of GnRH and gonadotropin secretion.  Intercavernous sinus 
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cannulation is a non surgical method used for collecting pituitary venous (PV) blood 
from horses.  The method involves inserting a cannula into the superficial facial vein 
and then directing the cannula along a venous pathway until the catheter comes to 
lie in the ICS at the outlet of the paired pituitary veins.  Intercavernous sinus 
cannulation allows measurement of GnRH and gonadotropin secretion that is not 
detectable in peripheral blood.   
Using PV blood samples it was demonstrated that in estrus and diestrus 
GnRH pulses are accompanied by LH and FSH pulses with significant coincidence, 
suggesting a signal-response relationship that GnRH is the primary secretagogue for 
LH and FSH (Irvine and Alexander, 1994).  The pulse frequency of GnRH affects the 
relative amounts of FSH and LH secreted.  As GnRH frequency increases during 
estrus, LH secretion rate increases.  In contrast, GnRH pulses are less rapid during 
diestrus while FSH increases.  Thus GnRH frequency determines the LH: FSH ratio, 
being high during estrus and low during diestrus.  Pulse frequency of both GnRH 
and gonadotropins increases during estrus leading to the ovulatory surge.  
Gonadotropin releasing hormone secretion has been found to be about three times 
greater during the ovulatory surge than in mid-diestrus.  The response of LH to 
GnRH during the periovulatory surge was four times greater than during mid-diestrus 
phase, suggesting that changes in pituitary responsiveness to GnRH play a major 
role in generating the mare’s ovulatory LH surge.  LuteinIzing hormone and FSH 
pulses measured in PV blood occur every 60-120 minutes in early estrus, increasing 
to 20-30 minutes as the peak of the ovulatory surge approaches (Irvine and 
Alexander, 1994).     
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1.3.2 Regulation of GnRH 
 There are various different regulators of GnRH secretion, many of which have 
been recently discovered and/or are not completely understood.  Environmental 
factors affect GnRH secretion (e.g.; photoperiod).  As mentioned previously, 
melatonin is secreted during hours of darkness in the anestrous season of the mare 
which lowers GnRH secretion.   
Opioids are peptides produced by the brain that modulate GnRH and 
gonadotropin secretion.  Opioids, acting as neurotransmitters, suppress the release 
of norepinephrine in the vicinity of GnRH-secreting neurons, removing a stimulus of 
GnRH secretion (McKinnon and Voss, 1993; Ginther, 1992).  The suppression of 
GnRH by opioids leads to an affect on gonadotropin release.  They also mediate the 
progesterone-induced suppression of LH secretion.  Naloxozone is a potent 
antagonist of the opioids and is used to test the physiological role of the opioids.  
Naloxozone induces small rises in GnRH, LH, and FSH secretion in estrous mares, 
demonstrating the inhibitory role of opioids (Davison et al., 1998).  
Circulating ovarian hormones regulate GnRH secretion as part of a hormonal 
feedback control mechanism (Figure 2).  Progesterone is secreted from luteal 
structures, primarily the corpus luteum.  Progesterone plays an inhibitory role on 
frequency of GnRH release via an opioid mediator as mentioned above.  The role of 
estradiol in regulation of GnRH secretion is complex and controversial.  Estradiol is 
produced by the maturing ovarian follicle.  High estradiol concentrations inhibit 
GnRH when progesterone levels are high, but exhibit a positive feedback effect on 
the hypothalamus, leading to an ovulatory LH surge, when progesterone levels are 
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low.  In the mare estradiol administration alone does not lead to either an ovulatory 
LH surge or a marked suppression of LH.  Combined treatment of estradiol with 
GnRH has been designed to mimic hormonal events of the periovulatory period, 
when the relative bioactivity of plasma LH increases (Alexander et al., 1984).  The 
combined estradiol-GnRH treatment results suggest that the interaction between 
estradiol and GnRH may produce this normal increase in LH bioactivity (McKinnon 
and Voss, 1993).  Inhibin is a glycoprotein hormone that has a specific effect on the 
secretion of FSH but does not or only minimally influences LH secretion.  Inhibin is 
mainly secreted by the granulosa cells and theca cells of large follicles in mares 
(Nagamine, 1998).  Inhibin concentrations increase prior to the decline of the 
follicular wave-stimulating FSH surge, indicating suppression of FSH before and 
during selection of the dominant follicle.  The circulating concentrations of FSH and 
inhibin are inversely related during estrous (Roser et al., 1994; Bergefelt et al., 
2001), and it has been shown that passive immunization against inhibin results in 
increased plasma FSH concentrations (Nambo et al., 1998; Nagamine et al., 1998; 
Donadeau and Ginther, 2001).           
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Figure 2. Hypothalamic-pituitary-gonadal axis feedback mechanisms in the female. 
 
Reproduced with permission from Geisert, R., 2005 
 
1.4 Endocrinology of the estrous cycle 
1.4.1 Follicular phase  
 The profiles of GnRH, FSH and LH change with the seasonality of the mare’s 
reproductive cycle.  The start of the breeding season is triggered by the increased 
length of daylight per day, resulting in a decrease of melatonin and an increase in 
GnRH secretion.  This increase in GnRH secretion induces LH and FSH secretion 
from the anterior pituitary.  The estrous cycle is repeated every 22 days in a cycling 
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non-pregnant mare (Samper, 2000).  The end of one estrous cycle and the start of 
another is marked by ovulation, often defined as Day 0.  The beginning of the 
follicular phase is determined by the end of the luteal phase that occurs due to the 
death of the corpus luteum (luteolysis), and concomitant decrease of progesterone 
production.  The emergence of follicular waves is attributed to a large increase in 
circulating concentrations of FSH.  Follicle stimulating hormone exerts its effect by 
binding to FSH receptors on the granulosa cells of ovarian follicles.  As a dominant 
follicle is selected increased systemic levels of estrogen and inhibin are released by 
the follicle, resulting in an FSH decrease via negative feedback at the hypothalamic-
pituitary axis.  After the selection of a dominant follicle there is a shift of the follicle 
from FSH responsiveness to LH responsiveness because the dominant follicle 
changes from primarily having FSH receptors to LH receptors.  Increasing LH levels 
are attributed to positive feedback at the hypothalamic-pituitary axis by estrogen 
during periods of lower progesterone.  Spontaneous ovulation results as the readied 
preovulatory follicle is exposed to high levels of LH.  Following the pattern of the LH 
surge in spontaneous ovulation, many induced ovulation methods have been 
created (Ginther, 1992; Samper, 2000).                           
1.4.2 Luteal phase       
 The beginning of the luteal phase is attributed to the formation of a corpus 
luteum following ovulation.  The rupture of the ovulatory follicle results in a 
decreased production of estrogen and inhibin, resulting in a decrease of both 
systemic LH and FSH.  The decrease in LH is due to the combined effect of the 
declining positive estrogen feedback and the increasing negative progesterone 
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feedback.  The transformation of granulosa cells into luteal cells (and the start of the 
formation of a corpus luteum) occurs shortly after ovulation.  The corpus luteum (CL) 
forms approximately 0-5 days in early diestrus, is mature on estrous cycle days 6-
13, and regresses beginning on estrous cycle day 14-16 (Samper, 2000).  
Termination of the luteal phase is a cascade of hormonal events with the end result 
being synthesis and a peak release of PGF2α by the endometrium.  The release of 
PGF2α results in luteolysis (death of the corpus luteum).  Systemic concentrations of 
PGF2-alpha reach peak concentrations by day 14; and PGF2α levels then begin to 
decrease concurrent with progesterone levels, signaling the end of the luteal phase 
(Ginther, 1992; McKinnon and Voss, 1993).  The end of the luteal phase transitions 
the mare back into the follicular phase, starting the estrous cycle over again. 
1.5 GnRH analogues/hormones used to control estrus 
1.5.1 Cattle 
 The four commercially available GnRH analogues approved by the U.S. FDA 
for use in cattle are Ovacyst/Fertelin™ (by Phoenix Scientific), Fertagyl™ (by 
Intervet), Cystorelin™ (by Merial) and Factrel™ (by Fort Dodge).  
Ovacyst/Fertelin™, Fertagyl™, and Cystorelin™ have the same active ingredient, 
gonadorelin diacetate tetrahydrate, whereas gonadorelin hydrochloride is the active 
ingredient in Factrel™.  These GnRH products have FDA approval for the treatment 
of ovarian follicular cysts in dairy cattle (Stewart et al., 2004).  These products are 
also commonly used in protocols for synchronization of ovulation in cattle, although 
their only FDA-approved use is for treatment of ovarian cysts. 
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 Reproductive inefficiency is a costly and production-limiting problem that 
faces both the dairy and beef cattle industries.  Synchronization of ovulation 
programs using GnRH analogues have been developed to decrease days open, 
optimize labor and service rate, and increase efficiency of artificial insemination (AI).  
Three common GnRH protocols have emerged to synchronize ovulation and/or 
estrus in cattle:  OvSynch, CO-Synch, and Select Synch (Figure 3).   
OvSynch 
OvSynch (Pursley et al., 1995) was originally created for use in dairy cattle, 
but the basic elements of the protocol also have benefits for use in beef cattle.  
OvSynch starts with the administration of GnRH followed by PGF2α seven days 
after GnRH and administration of a second GnRH injection two days after PGF2α 
treatment.  Cattle are then inseminated 16-24 hours after the second GnRH 
injection.  The first GnRH injection is to cause ovulation and the initiation of a new 
follicular wave.  PGF2α serves to lyse any CL, including those induced to form 
following the first GnRH injection.  The second GnRH injection is given to cause 
ovulation, to be followed by insemination 16-24 hours after the second GnRH 
injection (Kesler and Constantaras, 2004).  
CO-Synch   
The CO-Synch (Geary et al., 1998) protocol utilizes a similar strategy as 
OvSynch, but uses a single timed fixed AI at the time of the 2nd GnRH injection.  The 
CO-Synch protocol involves a GnRH injection followed seven days later by PGF2α.  
A second GnRH injection is given two days after PGF2α injection, and cows are 
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artificially inseminated in conjunction with the second GnRH injection (Patterson et 
al., 2002; Kesler and Constantaras, 2004).         
These GnRH protocols are designed to minimize the number of days that a 
cow is left open and to maximize the financial outcome from each cow.  Research 
has shown the GnRH-based protocols OvSynch and CO-Synch should not be used 
in heifers (Kesler and Constantaras, 2004).  The protocols have beneficial effects in 
cows but not in heifers or anestrous cows because of an inconsistent follicle wave 
pattern and a lack of a PGF2α responsive CL (Yaniz et al., 2004).    
Select Synch 
Select Synch (Geary et al., 2000) includes an injection of GnRH followed by 
PGF2α seven days later.  Cows synchronized with the Select Synch protocol are 
bred based upon the detection of estrus; usually 36 to 72 hours post PGF2α.  
Detection of estrus is currently recommended to begin as early as 4d after GnRH 
injection and continue through 6 d after PGF2α (Kojima et al., 2000).  The initial 
GnRH injection provokes a preovulatory-like LH surge, and the injection of PGF2α 
induces regression of corpora lutea if present (Patterson et al., 2002; Geary et al., 
2000). 
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Figure 3. Methods currently being used to synchronize ovulation in postpartum beef 
cows: OvSynch, CO—Synch, and Select Synch. 
   
Reproduced from Patterson et al., 2000. 
 
1.5.2 Horses 
 Horses are often acknowledged to have lower reproductive efficiency than 
that of other domestic animals (Johnson and Becker, 1993; Jones, 2006). The mare 
has lower reproductive efficiency than other domestic animals due to natural factors 
such as the seasonality of ovulation cycles, the erratic nature of the estrous cycles 
during transition periods, and variability in the duration of behavioral estrus between 
estrous cycles.  Factors imposed by humans also contribute to this low reproductive 
inefficiency such as selection based upon a horse’s pedigree and/or performance 
(and not on their reproductive performance) and an artificially hastened “breeding 
season” that precedes the horses’ natural breeding season (Ginther, 1992).    
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 Few GnRH or GnRH analogue products are available on the market for horse 
breeders.  The most commonly used GnRH products are deslorelin, a GnRH 
analogue marketed as Ovuplant™ by Fort Doge Animal Health and BioRelease™ by 
BET Pharm.   
hCG 
Although not a GnRH analogue, human chorionic gonadotropin (hCG) is 
commonly used for induction of ovulation in the mare because of its ability to bind 
LH receptors.  Typically, hCG is administered to mares with a minimum ovarian 
follicle diameter of 35 mm as a single injection of 1500 to 3300 IU to cause ovulation 
within 48 hours. There is contradictory literature concerning the formation of anti-
hCG antibodies after several successive hCG injections, resulting in a decline in the 
efficacy of hCG in timing or predicting ovulation. Briant et al. (2006) found the 
stimulatory effect of hCG on ovulation and LH was repeatable in three cycles during 
the season, suggesting that antibody formation may be functionally insignificant.  
Barbacini et al. (2000) attributed the decrease in the ability of hCG to predict the 
time of ovulation to seasonality and not the repeated use of hCG.  In contrast, Voss 
et al., (1975) showed that hCG treatment lengthened the time of estrus and 
increased the length of time from the onset of estrus until ovulation when used for 
three successive cycles.  A more recent study by McCue et al. (2004) noted a 
significant linear trend for a decline in efficacy at inducing a predicted or timed 
ovulation as the number of hCG treatments increased within a season.  Ovulation 
rate was significantly shorter (0-24 hours) after hCG in mares receiving the hormone 
on the third through fifth cycle of the year than for mares receiving hCG on the first 
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two cycles of the breeding season (48 hours).  Sullivan et al. (1973) found the 
efficacy of hCG to decrease in accurately timing ovulation when used more than 
twice during a single breeding season.  Duchamp et al. (1987) demonstrated that 
14/16 mares treated with 3 successive injections of hCG showed a measurable rise 
of antibodies. Roser et al. (1979) showed the anti-hCG antibodies can develop and 
persist between 30 days to several months after 2-4 injections of hCG.  The 
development of anti-hCG antibodies and decline in efficacy of timing ovulation create 
a need for a more dependable hormone to induce ovulation in mares. 
 PGF2α  (and analogues) 
 The use of PGF2α (and analogues) to time ovulation has resulted in 
inconsistent responses.   Prostaglandin (and analogues) acts indirectly on the 
hypophyseal-gonadal axis to affect ovulation.  Prostaglandin is administered to lyse 
the CL, therefore decreasing progesterone (P4) production.  When P4 levels are 
decreased GnRH storage is decreased and the GnRH release from the 
hypothalamus causes the release of LH and FSH.  Estradiol production by the 
follicle increases as FSH stimulates follicle growth.  This cascade of effects leads to 
follicle maturation and ovulation.  Squires et al. (1981) reported the increase of 
GnRH, LH, and FSH pulses measured in both pituitary venous and jugular blood in 
response to a PGF analogue.  The inconsistency of PGF2α (and analogues) to time 
ovulation was demonstrated in two different research studies.  Savage and Liptrap 
(1987) found that cycling mares (average follicle size 42.8 mm) treated with a 
PGF2α analogue ovulated at an average of 41.8 hours after treatment.  Harrison et 
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al. (1987) treated cyclic mares (average follicle size 42.0 mm) with a PGF2α 
analogue and reported an average of 4.7 days until ovulation.  
 Deslorelin Ovuplant™ 
Ovuplant™  was first approved by the U.S. FDA in 1999 for use in hastening 
ovulation in mares.  Ovuplant™ is a controlled release subcutaneous implant.  The 
active ingredient in Ovuplant™ is deslorelin, a nonapeptide analogue of the natural 
gonadotropin releasing hormone (European Agency for the Evaluation of Medicinal 
Products, 2002).  Ovuplant™ is administered in 2.1 mg doses to mares that have a 
minimum ovarian follicle diameter of 35 mm.   Meinert et al. (1993) reported that the 
deslorelin implant induced ovulation in 93% of mares 48 hours after insertion and 
63% of ovulations occurred 36 to 48 hours after implantation.  Endocrine profiles 
showed a sharp elevation of LH and FSH with peak levels at 12 hours after 
implantation and increased blood concentrations until 48 hours.  Similar findings 
were reported by Ganheim and Jöchle (1995), McKinnon et al. (1993), and Squires 
et al. (1994).    
A potential disadvantage to the use of deslorelin implants has been the need 
to remove the implants within two days after ovulation to prevent follicular 
suppression and delayed return to estrus.  McCue et al. (2000) found that mares 
treated with deslorelin acetate exhibited decreased pituitary FSH secretion during 
the diestrous period following ovulation.  The decreased FSH serum concentration 
may lead to decreased follicular development and a delay in the emergence of a 
dominant follicle, increasing the duration of the interovulatory period.  Johnson et al. 
(2002) obtained further evidence that deslorelin acetate treatment temporarily down 
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regulates the pituitary gland reporting deslorelin administration increased the 
interovulatory interval, consistently suppressed plasma LH and FSH concentrations, 
and resulted in a complete lack of responsiveness of anterior pituitary LH and FSH 
secretion to additional GnRH stimulation.  Studies have shown that removal of the 
deslorelin implant once ovulation is confirmed leads to no temporary down regulation 
of the pituitary gland, thus eliminating follicular suppression and delayed return to 
estrus due to the implant (Wendt et al., 2002; McCue et al., 2002).  Removal of the 
implant, however, may be objectionable and an inconvenience to mare practitioners 
and mare owners.   
The availability of deslorelin has affected its use in the U.S. equine breeding 
industry.  Ovuplant™ was withdrawn from the market and no longer available due to 
non-compliance with specific FDA regulations. (AspenBio Pharma, Inc, 2007).  
Deslorelin BioRelease 
Recent research has demonstrated that a short term release deslorelin 
product, BioRelease Deslorelin injection by BET Pharm, is effective in inducing 
ovulation (Stich et al., 2004).  The product is in a biocompatible liquid vehicle that is 
administered in a single dose by intramuscular injection.  Preliminary studies have 
shown that BioRelease Deslorelin injections of 1.5 mg given to mares with ovarian 
follicles with a diameter of 35 mm or greater results in ovulation within 48 hours 
(Fleury et al., 2003;  Stich et al., 2004).  Kolling and Allen (2004) demonstrated that 
0.75 mg or 1.5 mg doses were both successful in inducing ovulation within 48 hours 
in the majority of mares treated with BioRelease Deslorelin injections and suggested 
that this compound is a possible alternative to hCG and Ovuplant™.  Further studies 
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with larger numbers of mares are needed to confirm the findings of previous 
research studies.  
Kisspeptin 
Recent research has investigated the use of kisspeptin to hasten ovulation.  
Kisspeptin acts primarily by regulating GnRH secretion via a G protein-coupled 
receptor at the hypothalamic level, causing an increase in gonadotropin release.  
Specifically, Kisspepetin-10 has been shown to induce robust LH responses (and to 
a lower extent FSH) indicating its potential therapeutic use in pharmacological 
manipulation of the female gonadotropic axis (Gutierrez-Pascual, E., et al., 2007; 
Roa, J. et al., 2006; Messager, S. et al., 2005).   Briant et al. (2006) administered 10 
mg of human C-terminal decapeptide Kisspeptin-10, dissolved in sterile saline 
intravenously (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) when a follicle 
reached 33 mm.  Treated mares had shorter days from treatment to ovulation (2.00 
± 1.3 days) than control mares (4.25 ± 1.5 days).  The proportion of mares ovulating 
within 48 hours of injection were 6/8 (75%) for treatment mares and 2/8 (25%) for 
control mares (Briant et al., 2006).  This study provides evidence that Kisspeptin 
induced ovulation in mares, but more research is required before its efficacy can be 
determined as an effective treatment in inducing ovulation.                   
1.5.3 Cystorelin™ (gonadorelin diacetate tetrahydrate) 
 For the purpose of this thesis, Cystorelin™ will be the GnRH product 
discussed.  As mentioned previously the active ingredient of Cystorelin™ is 
gonadorelin diacetate tetrahydrate.  Gonadorelin is a decapeptide composed of the 
sequence of amino acids 5-oxoPro-His-Trp-Ser-Tyr-Gly-Leu-Narg-Pro-Gly-NH2.  
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Gonadorelin is the hypothalamic releasing factor responsible for the release of 
gonadotropins from the anterior pituitary.  The synthetic gonadorelin is 
physiologically and chemically identical to the endogenous bovine hypothalamic 
releasing factor (Merial.com).  Cystorelin™ was used in many of the experiments to 
determine the effectiveness of the OvSynch protocol.   
 Pursley (1995) used Cystorelin™ as the GnRH analogue in an OvSynch 
protocol stating that the OvSynch protocol “could have a major impact on managing 
reproduction in lactating dairy cows, because it allows for AI to occur at a known 
time of ovulation and eliminates the need for detection of estrus”.  Pursley et al. 
(1997) demonstrated with Cystorelin™ that the OvSynch protocol reduced the 
median days to conception by 19 days; thus, synchronization of ovulation provided 
an effective way to manage reproduction in lactating dairy cows by eliminating the 
need for detection of estrus.     
Martinez et al. (2003) evaluated the effects of Cystorelin™, Fertagyl™ and 
Factrel™ on dairy and beef cattle.  Cystorelin™ induced a greater LH release, 
resulting in a higher ovulatory rate in dairy cows, but not in beef heifers.  Cystorelin™ 
caused a greater total LH release than Factrel™ (Stevenson et al., 2000).  These 
results can be contributed to the fact that OvSynch protocol synchronizes follicular 
and luteal development in lactating cows but not in heifers as shown by Anderson 
(1998) in which Cystorelin™ was the GnRH analogue used.  Cystorelin™ has also 
been successfully used in Select-Synch (Stevenson et al., 2000; Geary et al., 2000; 
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Dejarnette et al., 2001), Co-Synch (Geary et al., 2001), and OvSynch (Pursley et al., 
1995) protocols. 
1.6 Rationale for experiment 
 The mare is a domestic species with many challenges pinpointing the exact 
time of ovulation.  The length of the period of estrus is highly variable, and the timing 
of ovulation within the period of estrus is also unpredictable. The use of hCG and 
deslorelin, as mentioned above, has adverse consequences and presents a 
challenge to the equine breeding industry.  The cattle industry has many different 
GnRH analogues available to potentially control the time of ovulation.  At present, it 
seems that no one has tested the effect of Cystorelin™ in horses to control the time 
of ovulation.  This experiment is designed to test the effectiveness of a cattle GnRH 
analogue, Cystorelin™, on inducing ovulation in the mare. 
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CHAPTER 2. INDUCTION OF OVULATION AND LH RESPONSE IN CYCLIC 
MARES TREATED WITH CYSTORELIN™ 
INTRODUCTION 
Regulating the time of ovulation in the mare has many practical and beneficial 
applications.  The increasing use of artificial insemination technologies in the equine 
industry has increased the importance of controlling the time of ovulation to improve 
management and labor efficiency, optimize the time of breeding when using 
transported semen, and reduce the number of times a mare is bred during a given 
estrous cycle.  In cyclic mares, human chorionic gonadotropin (hCG), prostaglandin 
F2alpha (PGF2α), and gonadotropin releasing hormone (GnRH) analogues have 
been used in attempts to control the time of ovulation.  A new product to time 
ovulation in the mare, EquiPure-LH (by AspenBio Pharma), is being investigated in 
the U.S. but research data on its efficacy has not been published.  
The repeated use of hCG to control the time of ovulation has yielded 
inconsistent results, largely due to its antigenic effects in the mare (Voss et al., 1975; 
McCue et al., 2004; Sullivan et al., 1973; Duchamp et al., 1987; Roser et al., 1979). 
The use of PGF2α (and analogues) to time ovulation has also resulted in 
inconsistent responses (Harrison et al.,1987; Savage and Liptrap, 1987; Squires et 
al.,1981).  The GnRH analogue deslorelin (Ovuplant™) reportedly causes 
suppressed gonadotropin secretion and desensitization to GnRH, which leads to an 
extended interval between induced ovulation and the subsequent ovulation, when 
Ovuplant™ is left in place for over 48 hours and the mare does not become pregnant 
(Johnson et al., 2002; McCue et al., 2000).   
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In other species such as cattle, exogenous GnRH has been used to 
effectively induce ovulation (Pursley et al., 1995; Geary et al., 2000).  The objective 
of the present study was to determine the effect of Cystorelin™ (gonadorelin 
diacetate tetrahydrate) on induction of ovulation and LH response in cyclic mares. 
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MATERIALS AND METHODS 
Experimental Animals 
A total of 24 Iowa State University mares was used in this study.  Mares were 
of Thoroughbred (n=9) and Stock type (Paint and Quarter Horse; n=15) breeding.  
The first trial (Trial A) was performed during the 2006 breeding season (May-June) 
using 6 mares, and the second trial (Trial B) was performed during the 2007 
breeding season (February-May) using 18 mares.  Throughout each breeding 
season mares were teased to a stallion to identify estrus.  When mares showed 
signs of estrus they were evaluated daily or every other day via transrectal 
ultrasonography to monitor ovarian follicle size.  Mares were kept in individual stalls 
during treatment periods with free choice hay and water.  All procedures performed 
with animals were reviewed and approved by the institutional animal care and use 
committee.   
Treatments 
Mares possessing an ovarian follicle 3.5 cm to 4.0 cm in diameter were 
randomly assigned to either treatment with gonadorelin diacetate tetrahydrate 
(Cystorelin™, Merial)1 or with sterile saline (control).   Treatment mares were given a 
75 µg (1.5 mL) i.m. injection of Cystorelin™  in the neck at 0, 120, and 240 minutes.  
Control mares were given three 1.5 mL injections of sterile saline at 0, 120, and 240 
minutes.  After the start of treatment, ultrasonography was performed daily until 
                                                 
1 Cystorelin™ is not approved by the U.S. Food and Drug Administration (FDA) for use in horses, and FDA has 
not determined that the product is safe and effective in horses. 
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ovulation was confirmed.  Across trials 17 treatment mares and 7 control mares 
were used.   
Blood sample collection 
 Blood samples were collected from treatment and control mares via an 
indwelling jugular catheter according to the timetable shown in Table 1.  Ten mL of 
blood was drawn 30 minutes prior to the initial injection (GnRH or saline), 
immediately prior to the initial injection, and at 30-minute intervals after the initial 
injection for six (Trial A) or 10 (Trial B) hours to measure LH.  In trial B, an additional 
blood sample was collected daily starting the day after treatment until ovulation was 
confirmed.  Blood samples were placed in heparinized tubes and were refrigerated 
briefly until centrifugation for 25 min at 3,000 RPM.  Plasma was harvested and 
stored frozen until assayed for LH.   
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Table 1. Timeline for blood sample collection and treatment with Cystorelin™ 
Day 1 (start of treatment) 
Time of day Cystorelin™ injection  Blood sample  Time line (min) 
1130   1 (prior to Cystorelin™) -30  
1200  1 2  (prior to Cystorelin™) 0  
1230   3 30  
1300  4 60  
1330   5 90  
1400  2 6 120  
1430   7 150  
1500  8 180  
1530  9 210  
1600 3 10 240  
1630  11 270  
1700  12 300  
1730  13 330  
1800*  14 360  
1830   15 390  
1900  16 420  
1930  17 450  
2000  18 480  
2030  19 510  
2100  20 540  
2130  21 570  
2200  22 600  
* last blood sample for Trial A 
Day 2 and daily afterwards until ovulation was documented 
Time of day Blood sample number Time line (min) 
0900  23 1260  
0900 24 2700 
0900 25 4140 
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Assay of plasma LH levels 
 Luteinizing hormone was measured in plasma by radioimmunoassay 
(Thomspon et al., 1983).  Intra-and interassay coefficients of variation and assay 
sensitivities were 6%, 9%, and 0.2 ng/mL, respectively.  
Data Analysis 
Data were analyzed using the GLM procedure of SAS for a completely 
randomized design (SAS Inst. Inc., Cary, NC) to test the effect of treatment and 
breed on days to ovulation and plasma LH levels.  LH means were calculated over 
four time periods [-30 to 0 (Period 1 (baseline mean)), 30-120 (Period 2), 150-240 
(Period 3), 270-360 min (Period 4)], and the LH response was analyzed by 
comparing the mean LH value of Period 2, 3, and 4 with Period 1 (baseline mean).  
Levene’s test (Levene, 1960) was used to analyze the variability in days to ovulation 
between treatment and control mares.   
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RESULTS 
Days to ovulation 
   The effect of year was tested and found to be non significant (P>.57), so 
data were pooled across years.  The diameter of the largest follicle at the time of 
treatment was not different (P>.42) between treatment (3.8 ± .03 cm) and control 
(3.8 ± .06) mares.  Mares treated with Cystorelin™ ovulated 2.25 ± .25 days after 
treatment which was one day earlier (P<.05) than control mares (3.25 ± .41).  Of the 
treatment mares, 71% (12/17) ovulated within 48 hours after treatment compared 
with 14% (1/7) of control mares (Table 2).  Treatment and control mares were not 
different (P>.81) for variability in days to ovulation.  
 
Table 2. Ovarian status and response to treatment with either Cystorelin™ or saline.  
  
Variable Cystorelin™ 
mares 
Control mares 
Follicle size (cm) 
at treatment* 
3.8 ± .03 3.8 ± .06 
   
Days to 
ovulation*  
2.25 ± .25a 3.25 ± .41b 
   
Hours to 
ovulation (post 
treatment) 
  
     24 6% (1/17) 0% (0/7) 
     48 65% (11/17) 14% (1/7) 
     72 6% (1/17) 43% (3/7) 
     ≥96 12% (2/17) 43% (3/7) 
No ovulation 12% (2/17) 0% (0/7) 
*Mean ± standard error of the mean (SEM) 
a,b Means with unlike superscripts differ (P<.05) 
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LH response  
Plasma LH values from time -30 to 360 minutes for Trial A and Trial B were 
analyzed for statistical analysis.  Mean plasma LH levels were calculated over four 
time periods [-30 to 0 (Period 1 (baseline mean)), 30-120 (Period 2), 150-240 
(Period 3), 270-360 min (Period 4)], and LH response was analyzed by comparing 
the mean LH value of Period 2, 3, and 4 with Period 1 (baseline mean).  Although 
the level in Period 2 tended (P<.07) to be higher than baseline, LH levels in Periods 
3 and 4 were not different from baseline (P>.15, P>.18 respectively) (Figure 7).  The 
LH profiles of individual mares are shown in Figures 4 and 5, and mean LH values 
averaged across treatments are illustrated in Figure 6. 
 
Figure 4.  LH profiles of individual mares treated with Cystorelin™. 
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Figure 5. LH profiles of individual mares treated with saline. 
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Figure 6. Average LH response of treatment and control mares. 
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Figure 7. Mean plasma LH increase over time between  
treatment and control mares. 
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DISCUSSION 
 
 Follicle diameter at the start of treatment (3.8 cm ± .03) in our experimental 
mares was comparable to that reported by others when using deslorelin (Ovuplant™) 
to induce ovulation (Squires et al., 1994; Mumford et al., 1995; McCue et al., 2000; 
Wendt et al., 2002). Our Cystorelin™ protocol was effective in hastening ovulation in 
mares by one day.  The result that 71% of treated mares ovulated within 48 hours 
after the Cystorelin™ injections is comparable to results obtained by others who 
investigated hCG (Sullivan et al., 1973; McCue et al., 2004)  and deslorelin 
BioRelease™ (Stich et al., 2004).  Variability in days to ovulation was similar 
between Cystorelin™ treated and control mares (P>.81), but this may be due to the 
relatively small number of experimental animals used in this study.   
Recent research has investigated the use of Kisspeptin to hasten ovulation 
(Briant et al., 2006).  Treatment mares had shorter days from treatment to ovulation 
(2.00 ± 1.3 days) than control mares (4.25 ± 1.5 days).  The proportion of mares 
ovulating within 48 hours of injection was 6/8 (75%) for treatment mares and 2/8 
(25%) for control mares, similar to our results.  Kisspepetin-10 has been shown to 
induce robust LH responses (and to a lower extent FSH) indicating its potential 
therapeutic use in pharmacological manipulation of the female gonadotropic axis 
(Gutierrez-Pascual et al., 2007; Roa et al., 2006; Messager et al., 2005).   
 Luteinizing hormone secretion patterns were similar between control and 
treatment mares, yet 71% of Cystorelin™ treated mares ovulated within 48 hours of 
treatment compared with 14% for control mares.  Although LH response was not 
statistically significant between treatment and control mares, there was a tendency 
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(P<.07) for elevated LH level after the first Cystorelin™ treatment (Figure 6). The lack 
of a significant increase in plasma LH responses could be due to the low dose of 
gonadorelin, individual variation among mares, or the relatively small number of 
experimental animals used in our study.  Interestingly, inconsistencies in LH 
response have been previously demonstrated.  Harrison et al. (1987) administered 
7.5 mg of luprostiol or placebo to mares on the first day estrus was exhibited, but 
gonadotropin levels did not significantly change in response to luprostiol injection.  
Jöchle et al. (1987) administered 7.5 mg of luprostiol to mares in late anestrus or the 
transitional phase.  In 7 out of the 8 mares treated with luprostiol there was an 
increase in gonadotropin concentrations in jugular blood.  Evans et al. (2006) 
performed an hCG dose-response study (2500, 1500, 500, or 0 IU hCG) for three 
successive cycles.  Human chorionic gonadotropin or saline was administered when 
the largest follicle reached ≥ 35 mm, and no effect of treatment was found on mean 
LH level.  Treatment with 2500 and 1500 IU of hCG, however, advanced the onset of 
the endogenous LH surge, and the profile of the advanced LH surge was similar to 
that associated with spontaneous ovulation.  These results imply that flexibility is 
present for the timing of the normal cascade of endocrine events which result in the 
ovulatory LH surge.  Furthermore, those researchers demonstrated that an 
endogenous LH surge may not be needed to cause ovulation of the dominant 
follicle.   
Briant et al. (2003) performed two experiments on the use of a GnRH 
antagonist with or without the use of hCG to control ovulation in mares.  For 
Experiment 1, mares were treated with vehicle or antarelix for 3 days when the 
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largest follicle reached 32 mm.  For Experiment 2, mares were treated with vehicle 
or antarelix for 6 days, and hCG (1600 IU, i.v.) was injected one day after start of 
treatment.  Fifty percent of mares treated with antarelix for three days  ovulated an 
average of one day earlier than controls, but the other 50% did not ovulate.  All 
mares treated with antarelix for 6 days ovulated the same time as control mares (2.8 
± 0.2 days after the beginning of treatment).  In both experiments mares treated with 
antarelix had suppressed LH after start of treatment, and the LH surge was 
completely abolished compared to controls, this despite the fact that ovulation 
occurred in some of the antarelix mares.  Briant et al. (2003) concluded that short 
and small elevations in plasma LH concentration in mares are sufficient to resume 
terminal follicular growth and ovulation.   Our data supports the findings of Evans et 
al. (2006) and Briant et al. (2003).   
Data from this experiment suggest that Cystorelin™ could be used in equine 
breeding management to hasten ovulation in mares.  Although we did not test this in 
our study, Cystorelin™ treatment potentially could be used to overcome problematic 
hCG antibody formation (as well as availability issues with deslorelin products).  This 
treatment protocol is practical for horse breeders to use and eliminates the 
inconvenience of needing a veterinarian to inject and remove Ovuplant™.  Further 
studies with increased mare numbers need to be conducted before recommending 
the use of Cystorelin™ in inducing ovulation in cyclic mares.  For example, few of 
the mares used in our study were bred due to the timing of the experiment and farm 
breeding management decisions, so data on post-treatment pregnancy rates are 
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needed.  Additional studies with slightly different protocols aimed at reducing 
variability on the time of ovulation are also warranted. 
In conclusion, three 75 µg doses of Cystorelin™, administered at two-hour 
intervals to mares possessing an ovarian follicle between 35 and 40 mm in diameter 
are effective in hastening ovulation.   
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